Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease

Aparna Sharma1 © Vibhor Sharma2

1 Department of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India
2 Medical Oncology, Hematology and Bone Marrow Transplant, Paras Hospitals, Gurugram, Haryana, India

Address for correspondence Vibhor Sharma, MD, DM, Senior Consultant, Medical Oncology, Hematology and Bone Marrow Transplant, Paras Hospitals, Gurugram 122002, Haryana, India (e-mail: drvibhoroncology@gmail.com).


The phase 3 REACH 3 trial1 investigates ruxolitinib compared with investigator’s choice of therapy for glucocorticoid refractory or dependent moderate to severe chronic graft versus host disease (GVHD). This REACH 3 study was done in patients who were 12 years or older with moderate to severe glucocorticoid refractory or dependent chronic GVHD. The drugs administered in investigator’s choice of therapy arm include everolimus, extracorporeal phototherapy, ibrutinib, imatinib, infliximab, low-dose methotrexate, mycophenolate mofetil, sirolimus, and rituximab. REACH 3 study shows improvement in overall response at 24 weeks in the patients’ arm administered with ruxolitinib compared with the control cohort (49.7% vs 25.6%, odds ratio 2.99, p < 0.001). Ruxolitinib also led to greater median failure-free survival (>18.6 vs. 5.7 months, hazard ratio 0.37, p < 0.001) and higher symptom response (24.2% vs 11%, odds ratio 2.62, p = 0.001). The dose of ruxolitinib used was 10 mg twice daily (bd). In REACH 1,2 a phase 2 study investigating the role of ruxolitinib in patients 12 years or older with grades 2 to 4 steroid refractory acute GVHD, the starting dose of ruxolitinib was 5 mg bd for first 3 days. It also included an option to increase the dosage to 10 mg bd in absence of cytopenia. In REACH 2 study,3 a phase 3 study evaluating ruxolitinib in patients 12 years or older with grades 2 to 4 steroid refractory acute GVHD, the planned dose of ruxolitinib was 10 mg bd. The median dose administered was 16.8 mg in two divided doses. In REACH 1 study, ruxolitinib could be tapered after day 180 in patients who achieved complete response or very good partial response in acute GVHD and had discontinued corticosteroids for at least 8 weeks. In REACH 2 study, tapering of ruxolitinib was allowed after day 56 in the responsive patients. In REACH 1 study, corticosteroids were tapered as per institutional guidelines, with physician discretion allowed. In REACH 2 study, continuation of glucocorticoids was allowed alongside ruxolitinib or control therapy. Wu et al4 have reported a weight-based dosing of ruxolitinib in chronic GVHD patients wherein patients having a weight more than 60 kg received 10 mg bd while patients ≤60 kg received 5 mg bd.

In REACH 3 study, 16.4% patients discontinued ruxolitinib due to adverse events. In REACH 3 study, grade ≥3 thrombocytopenia and anemia was noted in 15.2% and 12.7% of patients respectively in ruxolitinib arm and 10.1% and 7.6% of patients respectively in the arm receiving control therapy. The incidence of cytomegalovirus infections was 5.5% and 8.2% in ruxolitinib and control arm respectively. The incidence of grade ≥3 pneumonia in the patients of ruxolitinib arm and control arm was 8.5% and 9.5% respectively.

The authors in REACH 3 study have not reported the median dose of ruxolitinib administered. It is recommended that dose of ruxolitinib be reduced when coadministered with fluconazole.5,6 It would be worthwhile to have the author’s opinions regarding the use of lower-dose ruxolitinib coadministered with fluconazole, especially in resource constrained settings. The primary end point of REACH 3 study was the overall response at week 24. No reasoning has been given as to why week 24 was chosen as the end time point. In REACH 3 study, a higher overall response was seen in ruxolitinib arm than in control arm regardless of the organs involved. However, the response rates in lung and liver were unsatisfactory in both the patient arms. The response rate in lungs was 8.6 and 6.1% respectively in ruxolitinib and control arms. The response rate in liver was 24.4 and 21.7% respectively in ruxolitinib and control arm. This demonstrates that
treatment of chronic GVHD in case of the recovery of these organs can be very difficult. Over 50% of patients enrolled in this trial had acute GVHD. The authors have included patients who were treated with ruxolitinib for steroid refractory acute GVHD. The number of such patients and the response rates of ruxolitinib in this subset in chronic GVHD would be interesting to know. In REACH 3, patients treated previously with two or more systemic therapies for chronic GVHD in addition to glucocorticoids with or without calcineurin inhibitors were ineligible. Wu et al\(^4\) included patients who had received 1–6 lines of second-line therapies for chronic GVHD. The median time taken to respond to ruxolitinib and the data regarding nonresponders or patients who had early deteriorating effects from ruxolitinib arm in REACH 3 study would further aid in our understanding. The overall survival in the ruxolitinib responders versus nonresponders would also be interesting. The limitations of REACH 3 study include the absence of a strong end point such as glucocorticoid-free remission, and the presence of confounders including concomitant treatments. This makes the determination of the effect on glucocorticoid dose over time with ruxolitinib as compared with commonly used therapies difficult.

REACH 3 study leads to important practice-changing conclusions, especially regarding the use of ruxolitinib in steroid refractory chronic GVHD. In resource-limited settings as in our country, the administration of ruxolitinib with azole antifungals may help in reducing the dose and hence the financial burden. The use of ruxolitinib should be started earlier rather than later in the case of steroid refractory chronic GVHD.

Funding
None.

Conflict of Interest
None.

References